Donghua Zhang

This study tests a new treatment plan for adults with newly diagnosed acute myeloid leukemia (AML) who are not healthy enough for strong chemotherapy. The approach uses a drug called selinexor, either alone or with very low doses of other chemo drugs, to quickly reduce cancer cel…

This early study tests a new treatment called AcNK-Sup003 for people with relapsed or refractory B-cell non-Hodgkin lymphoma, a type of blood cancer that has not responded to standard therapies. The main goals are to see if the treatment is safe and to find the best dose. About 2…

This study tests a new cell therapy (BCMA-GPRC5D CAR-T) in 28 adults with relapsed/refractory multiple myeloma who have already tried three or more treatments. The goal is to see if this therapy can control the disease and improve survival. Participants receive a one-time infusio…

This study tests a two-step treatment for people with a tough type of leukemia (AML) that has come back or not responded to standard chemo. First, patients receive a special immune cell therapy (CLL1 CAR-T) to target cancer cells, followed by a stem cell transplant to rebuild a h…

This study is testing a new treatment called CAR-T cells for people with relapsed or hard-to-treat blood cancers that have a specific marker called CD7. The treatment involves taking a patient's own immune cells, modifying them to better attack cancer, and giving them back. The m…